Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 533

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 533
---
2021, the Company’s only member was a corporation, thus the Company was a wholly owned subsidiary of the corporation and considered a disregarded entity for United States tax purposes. Accordingly, no provision for federal and state income taxes is included in the financial statements for the years ended December 31, 2023 and 2022.

#### Comprehensive Loss
Comprehensive loss is equal to net loss as presented in the statements of operations for the years ended December 31, 2023 and 2022.

#### Net Loss per Member Unit
The Company calculates basic and diluted net loss per member unit in accordance with the two-class method required for participating securities. The Company has two classes of member units, which are referred to as Class A member units and Class B member units. Class B member units are allocated 51% of earnings and losses, and Class A member units are allocated 49% of earnings and losses. The two-class method requires net loss for the period to be allocated between the member units.

<div align='center'>F-77</div>

TABLE OF CONTENTS

LIMINATUS PHARMA, LLC NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2023 AND 2022 Basic net loss per member unit is computed by dividing net loss by the weighted-average number of member units outstanding during the period. Diluted net loss per member unit excludes the potential impact of the Company’s warrants and options because their effect would be anti-dilutive due to the Company’s net loss for the years presented. Since the Company had a net loss in the years presented, basic and diluted net loss per member unit is the same. The following table presents a reconciliation of the numerator and denominator used to compute basic and diluted net loss per member unit for each class of member units (in thousands, except member unit and per member unit information):

| ​                                                    
 ​                                                    | ​ 
 ​ | ​ 
 ​ | For the year ended December 31, 
 2023                            |   |            |   |   |   |         |   |            |   | ​ | ​ | 2022    |   |            |   |   |   |         |   |            |   | ​ 
 ​ |
|:-----------------------------------------------------|:--|:--|:--------------------------------|:--|-----------:|:--|:--|:--|:--------|:--|-----------:|:--|:--|:--|:--------|:--|-----------:|